Search Results

You are looking at 101 - 110 of 477 items for :

  • Refine by Access: All x
Clear All
Full access

Kenneth C. Anderson, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Shaji K. Kumar, Michaela Liedtke, Matthew Lunning, Noopur Raje, Frederic J. Reu, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead, and Rashmi Kumar

.2% (3 stringent CRs, 10 VGPRs, 18 PRs). Median response duration was 7.4 months and median time to progression was 3.7 months; the estimated 1-year OS rate was 65%. 22 Adverse events reported included fatigue (39.6%), anemia (33.0%), nausea (29.2%), and

Full access

Renuka Iyer and Kaunteya Reddy

in the placebo group. The most frequent treatment-related adverse events were stomatitis, rash, fatigue, diarrhea, and respiratory infections. Everolimus benefit was due to tumor stabilization in most cases. Promising phase II data prompted another

Full access

Michael Levy, Thomas Smith, Amy Alvarez-Perez, Anthony Back, Justin N. Baker, Anna C. Beck, Susan Block, Shalini Dalal, Maria Dans, Thomas R. Fitch, Jennifer Kapo, Jean S. Kutner, Elizabeth Kvale, Sumathi Misra, William Mitchell, Diane G. Portman, Todd M. Sauer, David Spiegel, Linda Sutton, Eytan Szmuilowicz, Robert M. Taylor, Jennifer Temel, Roma Tickoo, Susan G. Urba, Elizabeth Weinstein, Finly Zachariah, Mary Anne Bergman, and Jillian L. Scavone

assessed are pain, dyspnea, anorexia, cachexia, nausea, vomiting, constipation, malignant bowel obstruction, fatigue, weakness, asthenia, insomnia, daytime sedation, and delirium. 4 Palliative interventions for these symptoms are discussed individually in

Full access

Boyu Hu, Jay L. Patel, Randa Tao, Richard B. Cannon, Marcus Monroe, and Gaurav Goyal

lesion and most of the cervical lymph nodes. After 7 months of therapy, trametinib dose was decreased to 1.5 mg daily due to the patient experiencing grade 2 fatigue, peripheral edema, and acneiform rash. At 1 year of therapy with trametinib, the patient

Full access

Margaret Tempero

quite a while, and travel restrictions remain in effect, which is fine, because all the big professional meetings we enjoy each spring and summer are being held virtually for the second year in a row. I do have mask fatigue, though. I don’t find

Full access

Rebecca M. Shulman, David S. Weinberg, Eric A. Ross, Karen Ruth, Glenn F. Rall, Anthony J. Olszanski, James Helstrom, Michael J. Hall, Julia Judd, David Y.T. Chen, Robert G. Uzzo, Timothy P. Dougherty, Riley Williams, Daniel M. Geynisman, Carolyn Y. Fang, Richard I. Fisher, Marshall Strother, Erica Huelsmann, Sunil Adige, Peter D. Whooley, Kevin Zarrabi, Brinda Gupta, Pritish Iyer, Melissa McShane, Hilario Yankey, Charles T. Lee, Nina Burbure, Lauren E. Laderman, Julie Giurintano, Samuel Reiss, and Eric M. Horwitz

fatigue, joint pain, fever, chills, headache, and nausea. Allergic reactions were rare after both dose 1 (6/1,752) and dose 2 (9/1,261). Postvaccination symptoms for all patients were more likely to be reported by women than by men (77.8% vs 65.5%; P

Full access

within 5 years of diagnosis. Carcinoids are generally slow-growing tumors, but in the advanced setting can be very disabling and impact quality of life (QoL) due to diarrhea, bowel obstructions, pain, weight loss, depression, and fatigue. Many of the

Full access

REMS. The table below reflects a sample of drugs recently added that may be used for a supportive care indication (e.g., pain, cancer-related fatigue) in a patient with cancer. All the drugs listed require the provision of a medication guide detailing

Full access

, but in the advanced setting can be very disabling and can impact quality of life (QOL) due to diarrhea, bowel obstructions, pain, weight loss, depression, and fatigue. Many of the abdominal symptoms are caused by the dense adhesions. Midgut carcinoids

Full access

David Cella, Sarah K. Rosenbloom, Jennifer L. Beaumont, Susan E. Yount, Diane Paul, Debra Hampton, Amy P. Abernethy, Paul B. Jacobsen, Karen Syrjala, and Jamie H. Von Roenn

symptoms specific to a given tumor can represent efficacy in achieving a meaningful patient outcome. Most validated measures of cancer-specific quality of life incorporate an assessment of certain prevalent symptoms, such as pain and fatigue, within a